Drugs that contain Rifaximin
1. Drug name - XIFAXAN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months from now) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months from now) | |
| US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months from now) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 8 months from now) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months from now) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(2 years from now) | |
| US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(4 years from now) | |
| CN1613858A | SALIX PHARMS | Polymorph Of Rifaximin, Preparation Method Thereof And Its Application In Medical Preparation |
Apr, 2007
(15 years ago) | |
| CN101260114A | SALIX PHARMS | Polymorphous Forms Of Rifaximin, Preparation Method For Their Production And Use Thereof In Medicinal Preparations |
Mar, 2024
(1 year, 5 months from now) | |
| CN101260115A | SALIX PHARMS | Polycrystalline Type Of Rifaximin, Production Method Thereof And Use Thereof In Medicinal Preparations |
Mar, 2024
(1 year, 5 months from now) | |
| CN101260114B | SALIX PHARMS | Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Mar, 2024
(1 year, 5 months from now) | |
| CN1886408B | SALIX PHARMS | Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Mar, 2024
(1 year, 5 months from now) | |
| CN1886408A | SALIX PHARMS | Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Mar, 2024
(1 year, 5 months from now) | |
| CN101260115B | SALIX PHARMS | Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Mar, 2024
(1 year, 5 months from now) | |
| CN1900077B | SALIX PHARMS | New Polymorphous Forms Of Rifaximin, Processes For Their Preparation And Use Thereof In Medicinal Preparations |
Jul, 2025
(2 years from now) | |
| CN1900077A | SALIX PHARMS | New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations |
Jul, 2025
(2 years from now) | |
| IN200800106P1 | SALIX PHARMS | Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Nov, 2024
(2 years from now) | |
| IN216296B | SALIX PHARMS | Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Nov, 2024
(2 years from now) | |
| IN200503181P1 | SALIX PHARMS | Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Nov, 2024
(2 years from now) | |
| IN254839B | SALIX PHARMS | Polymorphic Forms Of Rifaximin, Processes For Their Production And Use Thereof In Medicinal Preparations |
Nov, 2024
(2 years from now) | |
| IN280906B | SALIX PHARMS | New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations |
Jul, 2025
(2 years from now) | |
| IN200501865I1 | SALIX PHARMS | New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations |
Jul, 2025
(2 years from now) | |
| EP1676848B1 | SALIX PHARMS | Polymorphous Forms Of Rifaximin As Antibiotics |
Mar, 2024
(1 year, 5 months from now) | |
| EP1557421A1 | SALIX PHARMS | Polymorphous Form Of Rifaximin As Antibiotic |
Mar, 2024
(1 year, 5 months from now) | |
| EP1676847A1 | SALIX PHARMS | Polymorphous Forms Of Rifaximin As Antibiotics |
Mar, 2024
(1 year, 5 months from now) | |
| EP1676848A1 | SALIX PHARMS | Polymorphous Forms Of Rifaximin As Antibiotics |
Mar, 2024
(1 year, 5 months from now) | |
| EP1557421B1 | SALIX PHARMS | Polymorphous Form Of Rifaximin As Antibiotic |
Mar, 2024
(1 year, 5 months from now) | |
| EP1676847B1 | SALIX PHARMS | Polymorphous Forms Of Rifaximin As Antibiotics |
Mar, 2024
(1 year, 5 months from now) | |
| EP1698630A1 | SALIX PHARMS | New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations |
Mar, 2025
(2 years from now) | |
| EP1698630B1 | SALIX PHARMS | New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations |
Mar, 2025
(2 years from now) | |
| EP1698630A8 | SALIX PHARMS | New Polymorphous Forms Of Rifaximin, Processes For Their Production And Use Thereof In The Medicinal Preparations |
Mar, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months from now) | |
| US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months from now) | |
| US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(2 years from now) | |
| US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
| US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(6 years from now) | |
| US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(6 years from now) | |
| US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(6 years from now) | |
| US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
| US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(7 years from now) | |
| US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(7 years from now) | |
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; reduction in risk of overt hepatic encephalopathy (he) recurrence in adults; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in risk of overt hepatic encephalopathy (he) recurrence; Treatment of patients with hepatic encephalopathy (he); Method of treating travelers' diarrhea; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; Reduction in risk of overt hepatic encephalopathy (he) in adults
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | TABLET;ORAL | Prescription |
| 550MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.